Gilead Sciences Inc. on Thursday posted a higher-than-expected quarterly profit, helped by demand for its COVID-19 antiviral treatment, Veklury.
Gilead Sciences Inc. on Thursday posted a higher-than-expected quarterly profit, helped by demand for its COVID-19 antiviral treatment, Veklury.
This website, like most media sites, uses small files called cookies to anonymously customize the advertising that you see. Learn more about how we use cookies in our cookie policy.
